Pemetrexed (Alimta)

Phase I Clinical Trial Yields Positive Results In Latest Immunotherapy Treatment

The immune system is the body’s first line of defense when fighting off any illness, attacking foreign organisms or other substances that may harm or threaten the over health of the body. When the immune system is compromised, the body is unable to fight infections and becomes weak as the[…]

Read More »

Peripheral Neuropathy Pain Reduced in Mesothelioma Patients

Avastin (bevacizumab) is a type of chemotherapy treatment that slows tumor growth by blocking the protein that is responsible for forming new blood vessels, which is what tumors need to thrive. By blocking these blood vessels, tumor growth is slowed. For those suffering from mesothelioma, hindering tumor growth can greatly[…]

Read More »

Less than Half of Cancer Patients Eligible for Immunotherapy Treatments

In late 2017, the FDA approved Keytruda (pembrolizumab) as an immunotherapy treatment for cancer.  It’s typically used to treat inoperable metastatic non-small cell lung cancer and melanoma but it has also been approved by the FDA to treat any unresectable or metastatic solid tumor, such as those found in mesothelioma.[…]

Read More »

Potential New Treatment Acts as a Sealant for Pleural Mesothelioma Tumors

Pleural mesothelioma, caused by exposure to asbestos is a rare cancer – only 3,000 cases are diagnosed in the U.S. each year – but it is highly aggressive. There is no cure for plural mesothelioma but findings published in the Journal of Thoracic and Cardiovascular Surgery reveal that a new[…]

Read More »

First FDA Approved Treatment for Mesothelioma in 15 Years

In the Fall of 2018 scientists and researchers from Novocure, an oncology company that specializes in treating solid tumors, were hopeful their latest success with Tumor Treating Fields therapy would lead to FDA approval and ultimately, more options for those suffering from mesothelioma. After a successful clinical trial, these hopes[…]

Read More »

Currently Recruiting: Mesothelioma Clinical Trials

When it comes to effective mesothelioma treatments, options are unfortunately limited. There is no cure for mesothelioma and first line chemotherapy treatment Alimta, is no guarantee.  Many who are suffering from mesothelioma, who have found little or no comfort in traditional treatments, may turn to clinical trials for hope.  Through[…]

Read More »

Survival Factors for Mesothelioma Highlighted by University of Pittsburgh Medical Center

According to GLOBOCAN 2018 statistics, each year there are 30,443 mesothelioma cases worldwide, and of those 30,443, 25,576 pass away.  With close to 85 percent of those diagnosed succumbing to the disease, mesothelioma remains one of the most deadly cancers as there is no cure. However, surviving a mesothelioma diagnosis[…]

Read More »

UK Pharmaceutical Company’s Potential Cancer Vaccine Assists in Treating Mesothelioma

Combination treatment therapies are common for those suffering from mesothelioma because the aggressive nature of this asbestos-caused disease makes it difficult to treat effectively.  Ongoing developments and advancements in medicine have also helped mesothelioma patients extend their life and manage pain throughout the years. While there is no cure for[…]

Read More »

Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results

Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year –[…]

Read More »

Why is Chemotherapy Often Ineffective in Those Suffering from Mesothelioma?

Mesothelioma is a difficult cancer to treat for a multitude of reasons. A mesothelioma diagnosis is rare – only about 3,000 people per year in the United States are diagnosed – and this can make it difficult to study, given that there is generally a very small sample of patients[…]

Read More »